Previous Close | 6.18 |
Open | 6.32 |
Bid | 6.03 x 1400 |
Ask | 6.54 x 3100 |
Day's Range | 6.19 - 6.37 |
52 Week Range | 5.31 - 7.26 |
Volume | |
Avg. Volume | 758,087 |
Market Cap | 676.2M |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.32 (5.12%) |
Ex-Dividend Date | May 16, 2024 |
1y Target Est | N/A |
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three months ended March 31, 2024.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.